The company and all members of the board of directors guarantee that the content of the information disclosure is true, accurate and complete, and there are no false records, misleading statements or major omissions.

　　I. Overview of relevant situation

　　On September 30, 2019, Resverlogix Corp., a joint stock company of Shenzhen Haipurui Pharmaceutical Group Co., Ltd. (hereinafter referred to as “the company”), released the top line data of the phase III clinical trial of the innovative drug variety RVX-208 (Apabetalone). ToplineData) results are as follows:

　　1. The top-line data of phase III clinical trials of RVX-208 showed that the primary clinical endpoint was not reached (for patients with high-risk type 2 diabetes with acute coronary syndrome and low-density lipoprotein cholesterol in the near future, combined with standard therapy) The incidence of major cardiovascular adverse events). Major cardiovascular adverse events (MACE) were defined as cardiovascular death, nonfatal MI, and stroke.

　　2. Apabetalone shows tolerance and safety.

　　3. The main clinical results will be announced at the 2019 Annual Meeting of the American Heart Association (AHA).

　　4. Based on the results of clinical trials, RVX will continue to advance the RVX-208 project.

　　Second, the impact on the company

　　As of June 30, 2019, the company's book balance of RVX long-term equity investment was RMB 241,226,432.27. RVX shares fluctuated sharply due to the fact that the top-line data of Phase III clinical trials of innovative drug varieties did not reach the main clinical endpoint. As of the date of this announcement, the company does not need to make provision for impairment of the equity investment in accordance with relevant accounting standards.

　　Once the RVX stock price fluctuations and other factors cause the company to make provision for asset impairment of the equity investment, the company will perform the review and disclosure procedures in accordance with accounting standards and relevant regulations.

　　The clinical results have no significant impact on the company's production and operation activities, and will not have a substantial impact on the company's investment and layout of innovative drugs. The company will continue to promote the clinical development of existing innovative drug varieties.

　　Third, important tips

　　"Securities Times", "Securities Daily", "China Securities Journal", "Shanghai Securities News" and Juchao Information Network (www.cninfo.com.cn) selected the information disclosure media for the company. All information of the company is The information published in the above designated media shall prevail. The company will strictly fulfill its information disclosure obligations in strict accordance with the relevant laws and regulations and requirements, and do a good job in information disclosure in a timely manner.

　　The company solemnly invites investors to pay attention: investors should fully understand the stock market risks and risk factors disclosed in the company's periodic reports, pay attention to risks, prudent decision-making, and rational investment.

　　Special announcement.

　　Shenzhen Haipu Rui Pharmaceutical Group Co., Ltd.